Get the latest news, insights, and market updates on IRD (Opus Genetics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Opus Genetics Announces $25 Million Private Placement
RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that it has entered into a securities purchase agreement for a private placement (the “private placement”) of 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock at a pr Feb 13, 2026 - $IRD
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences. Collaborative Community on Ophthalmic Innovation (CCOI) Topic: Opus Genetics Feb 2, 2026 - $IRD
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
The trial is funded through Abu Dhabi’s Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026MERTK-related retinitis pigmentosa affects an estimated 60,000 patients worldwide RESEARCH TRIANGLE PARK, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRD Jan 27, 2026 - $IRD
Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
Live panel presentation on Tuesday, January 13th at 8:00 AM PTSOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Dr. Timothy Lu, Co-Founder and CEO, will participate as a panelist alongside Jonah Comstock, Editor in Chief, pharmaphorum; Jay Hartenbach, President & COO, Diakonos Jan 9, 2026 - $IRD
Opus Genetics highlights 2025 progress, upcoming 2026 catalysts
Opus Genetics (IRD) highlighted its progress achieved during 2025 and upcoming catalysts in 2026. OPGx-BEST1: First participant dosed in Phase 1/2 trial with enrollment ongoing. Initial data expected this quarter at Macula Society with 3-month results from the entire Cohort 1 expected in mid-2026. OPGx-BEST1 is potentially eligible for multiple regulatory designations which the Company expects to file for in 2026. OPGx-LCA5: Enrollment ongoing in run-in period for planned, adaptive pivotal Phase Jan 9, 2026 - $IRD
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
- Multi-asset pipeline with significant targeted data readouts and milestones -- Two lead ophthalmic gene therapy programs in clinical trials with new data anticipated in 2026 -- Supplemental New Drug Application (sNDA) submitted for partnered presbyopia treatment - - Corporate presentation at J.P. Morgan Healthcare Conference on Thursday, January 15, at 8:15 a.m. PT - RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company,” “Opus,” or “Op Jan 8, 2026 - $IRD
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the Compensation Committee of its Board of Directors approved an equity award under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to one non-e Dec 16, 2025 - $IRD
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple